Cheetah Medical's Noninvasive Hemodynamic Monitoring Technology Found to be a Highly Accurate and Promising Tool in Patients With Pulmonary Hypertension

TEL AVIV, Israel and PORTLAND, Oregon, May 18, 2011 /PRNewswire/ -- Results from a study validating Cheetah Medical's noninvasive NICOM(R) system specifically for use in patients with pulmonary hypertension were presented Wednesday, May 18th, at the 2011 American Thoracic Society Annual Meeting in Denver.

Pulmonary hypertension (PH) is a life threatening condition that affects the heart and lungs. The cause is gradual narrowing of the lung's arteries which severely impedes blood to flow normally from the heart through the lungs. This means the heart has to work harder than normal to push the blood through the lungs. Over time, the heart weakens and cannot keep up so that blood flow decreases. Eventually, the heart becomes so weak that it can't pump enough blood to meet the demands of the body, even at rest, which leads to the debilitating symptoms of heart failure such as shortness of breath at rest or during minimal activity (for example, climbing two flights of stairs), tiredness, swelling of the legs and stomach, and palpitations (abnormal heartbeats).

Clinicians have been seeking better ways to monitor disease progression in order to refine treatment. However traditional methods to asses patients' hemodynamic parameters, and most notably patients' cardiac output (CO), are highly invasive and thus suboptimal for routine serial assessment of PH.

In this study, the Cheetah Medical NICOM(R) Noninvasive Cardiac Output & Hemodynamic Monitoring System was used to monitor the hemodynamic performance of 25 pulmonary hypertension patients. University of Chicago researchers compared the results obtained with NICOM to those obtained with two gold-standard methods which are also invasive, the pulmonary artery catheter, also known as Swan-Ganz catheter, and the Fick method. The NICOM system provided equally accurate and precise measurements to the standard methods, but was completely non-invasive.

Stuart Rich, MD, Professor of Medicine at the University of Chicago and the study's Principle Investigator, said: "Survival in patients with pulmonary hypertension is closely linked to their cardiac output. However, because cardiac output measurements have required invasive cardiac catheterization, patients do not have this measured often. With the validation of a simple noninvasive technique to measure cardiac output in these patients, physicians should now be able to evaluate their patients' status frequently, and better judge the efficacy of their treatments."

Researchers hope that these findings will encourage use of CO monitoring not only into routine clinical practice to provide objective means of tracking changes in disease status and response to therapy, but will also pave the way to explore the utility of this technique in clinical trials as an early screening tool for differentiating effective versus non-effective treatments for PH.

About Cheetah Medical

Cheetah Medical's NICOM(R) Noninvasive Cardiac Output and Hemodynamic Monitoring System uses the company's proprietary BIOREACTANCE(R) Technology to deliver continuous, accurate, noninvasive cardiac output (CO) and other vital hemodynamic monitoring parameters, useful for fluid management and drug titration. The system is US FDA cleared and CE Marked, and since its commercial launch in 2008 has been adopted by a growing number of clinicians worldwide. Cheetah Medical headquarters is located in Tel-Aviv, Israel and its United States headquarters is located in Portland, Oregon. For more information, visit our website at http://www.cheetah-medical.com.

    For More Information Contact:
    Yoav Avidor, MD
    Chief Executive Officer
    Cheetah Medical Inc.
    [email protected]
    Telephone: +972-3-644-0288

SOURCE Cheetah Medical Ltd